Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the venous thromboembolism (a term that refers to both deep vein thrombosis and pulmonary embolism) drug market will be more than three times larger in 2013 because of the use of novel agents and an increase in the number of people receiving prophylaxis for the condition. According to a new Pharmacor study entitled Venous Thromboembolism, sales in this market will total $5.1 billion in 2013.

"Trials demonstrating the benefits of venous thromboembolism prophylaxis in lower-risk patients are proving that prophylaxis is a vital component of many surgical procedures," said Mark Thornton, M.Sc., Ph.D., analyst at Decision Resources. "In addition, by 2013, the oral direct thrombin inhibitor ximelagtran will replace vitamin K antagonists in a significant number of patients undergoing treatment for deep vein thrombosis and pulmonary embolism. However, opportunity still exists for other novel agents, such as the direct factor Xa inhibitors."

About Venous Thromboembolism

Deep vein thrombosis and pulmonary embolism are major causes of morbidity and mortality in hospitalized patients in the major pharmaceutical markets. Researchers estimate that the mortality rate of pulmonary embolism at six months approaches 20%. Failure to diagnose and administer treatment for deep vein thrombosis and pulmonary embolism has made them the most common causes of unexpected death in hospitalized patients and a major focus of medical malpractice lawsuits in the United States.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-
2563, emarshall@dresources.com

Reimbursement a Major Challenge for the Growth of Expensive Biologic Agents in the Rheumatoid Arthritis Market

View Now